

items.¹⁶ In the event that a company, entity, or person on the list appears to match that of a customer or other recipient, additional due diligence should be conducted before proceeding. There may be a strict export prohibition, a requirement for seeking a license application, or other evaluation of the Customer or other recipient necessary to ensure it does not result in an activity prohibited by any U.S. export regulations, or other restrictions. Before fulfilling the order, to ensure full compliance with all the terms and conditions of the restrictions placed on the parties on this list, the Provider must check the official publication of restricted parties in the **Federal Register**.

VII. Following Up With the U.S. Government in Cases Where Malintent is Suspected by Providers, Third-Party Vendors, or Manufacturers

If sequence or Customer screening raises concerns that are not alleviated through follow-up screening, Providers, Third-Party Vendors, and Manufacturers should not fulfill the order and are strongly encouraged to contact their nearest FBI Field Office's WMD Coordinator. Institutions are encouraged to work with their Principal Users and End Users to help them understand that only individuals with legitimate, *bona fide*, and peaceful purpose should obtain synthetic nucleic acids containing SOC's.

VIII. Records Retention

The *Guidance* recommends that Providers, Third-Party Vendors, and Manufacturers retain the following types of records for at least three years, and longer (e.g., eight years) if this does not pose an undue burden on their operations:

- Records of Customer orders including the following information: Customer information (point-of contact name, organization, address, email, and phone number), order sequence information (nucleotide sequences ordered, vector used), and order information (date placed and shipped, shipping address, receiver name);
- Records of protocols for sequence screening and for determining whether a sequence hit qualifies as a SOC;
- Records of screening documentation of all hits, even if the order was deemed acceptable;
- Records of any follow-up screening, even if the order was ultimately filled; and

- The ultimate disposition of any SOC orders, with documentation of reasoning for final decision (fulfill versus deny).

IX. Periodic Review, Evaluation, and Improvement of This Guidance

This *Guidance* addresses biosecurity risks that have emerged in a dynamic and rapidly developing technological landscape. It is likely that new risks will emerge and that new technological approaches will also appear to address them. As such, this *Guidance* encourages the further development of mechanisms to detect SOC's and screening strategies for sequences that contribute directly to pathogenicity and toxicity. For instance, strategies may be used by malicious Customers to obfuscate SOC's, including engineering pathogenic or toxic proteins with completely novel sequences. In such cases, synthetic nucleic acid orders may contain 50 nt windows that are not a match to any known sequence. Although there are likely legitimate explanations for orders of sequences with no matches in existing databases (e.g., nucleic acids ordered to populate microarrays or to store digital information), in such cases, it may be possible to use predictive bioinformatic algorithms to screen sequences that are not a match to any known sequences to determine if they could produce proteins that are structurally and functionally identical to SOC's. This *Guidance* encourages Providers to continue to develop these methods to best ensure the safety and security of the synthetic nucleic acid research enterprise.

This *Guidance* will be periodically revisited, including by soliciting stakeholder input, and feedback is encouraged from the nucleic acid synthesis industry as well as from their customers as they implement the *Guidance*. Furthermore, implementation of this *Guidance* will be supported through the publication of a Companion Guide.

Dawn O'Connell,

Assistant Secretary for Preparedness and Response.

[FR Doc. 2023–22540 Filed 10–12–23; 8:45 am]

BILLING CODE 4150–37–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Biomedical Advanced Research and Development Authority Industry Day 2023

AGENCY: Administration for Strategic Preparedness and Response (ASPR),

Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Biomedical Advanced Research and Development Authority (BARDA) annually hosts BARDA Industry Day (BID), a two-day conference with industry and our government partners to share BARDA's goals and objectives, increase awareness of U.S. government medical countermeasure (MCM) priorities, and facilitate collaboration between public and private sectors within the health security space. This year, BARDA plans to discuss implementation efforts for our *2022–2026 Strategic Plan*, which focuses on strengthening the health security of the nation, embracing lessons learned from the COVID–19 pandemic, incorporating new avenues of promising research and development, and addressing the imperative for MCMs that are safe, effective, and widely accessible.

DATES: BID 2023 will be a hybrid event, held from Monday, November 13–Tuesday, November 14, 2023. The meeting will begin each day at 9 a.m. Eastern Standard Time.

ADDRESSES: This meeting is open to the public. Register here: <https://medicalcountermeasures.gov/barda/barda-industry-day-2023/>.

FOR FURTHER INFORMATION CONTACT: Ezinne N. Ebi, Biomedical Advanced Research & Development Authority (BARDA), ezinne.ebi@hhs.gov, (202) 989–5539.

Dawn O'Connell,

Assistant Secretary for Preparedness and Response.

[FR Doc. 2023–22539 Filed 10–12–23; 8:45 am]

BILLING CODE 4150–37–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering.

The meeting will be open to the public by videocast as indicated below. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should

¹⁶ <https://www.trade.gov/consolidated-screening-list>.

notify the contact person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<https://videocast.nih.gov/>).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Biomedical Imaging and Bioengineering NACBIB, January 2024.

Date: January 23, 2024.

Open: 12:00 p.m. to 2:50 p.m.

Agenda: Report from the Institute Director, Council Members and other Institute Staff.

Place: National Institutes of Health, Democracy II, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Closed: 3:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, Democracy II, 6707 Democracy Boulevard, Bethesda, MD 20892.

Contact Person: Kathy Salaita, Sc.D., Acting Associate Director for Research Administration, Office of Research Administration, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Bethesda, MD 20892, kathy.salaita@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <https://www.nibib.nih.gov/about-nibib/advisory-council> where an agenda and any additional information for the meeting will be posted when available.

Dated: October 10, 2023.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-22672 Filed 10-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; RM1 HEAL Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices.

Date: November 6, 2023.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Ana Olariu, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301-496-9223, Ana.Olariu@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS.)

Dated: October 6, 2023.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-22618 Filed 10-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Office of Research Infrastructure Programs Special Emphasis Panel Office of Research Infrastructure Programs (ORIP) Special Emphasis Panel: Applications for Scientific Conferences.

Date: November 13, 2023.

Time: 1:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tatiana V. Cohen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301-455-2364, tatiana.cohen@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: September 29, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-22516 Filed 10-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and